OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study
Elias Dakwar, Edward V. Nunes, Carl L. Hart, et al.
Neuropharmacology (2018) Vol. 142, pp. 270-276
Open Access | Times Cited: 64
Elias Dakwar, Edward V. Nunes, Carl L. Hart, et al.
Neuropharmacology (2018) Vol. 142, pp. 270-276
Open Access | Times Cited: 64
Showing 1-25 of 64 citing articles:
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David Nutt, et al.
Acta Psychiatrica Scandinavica (2020) Vol. 143, Iss. 2, pp. 101-118
Closed Access | Times Cited: 253
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David Nutt, et al.
Acta Psychiatrica Scandinavica (2020) Vol. 143, Iss. 2, pp. 101-118
Closed Access | Times Cited: 253
Effects of psilocybin therapy on personality structure
David Erritzøe, Leor Roseman, Matthew M. Nour, et al.
Acta Psychiatrica Scandinavica (2018) Vol. 138, Iss. 5, pp. 368-378
Open Access | Times Cited: 223
David Erritzøe, Leor Roseman, Matthew M. Nour, et al.
Acta Psychiatrica Scandinavica (2018) Vol. 138, Iss. 5, pp. 368-378
Open Access | Times Cited: 223
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 166
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 166
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 153
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 153
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman, et al.
BJPsych Open (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 122
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman, et al.
BJPsych Open (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 122
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review
Nina Schimmers, Joost J. Breeksema, Sanne Y. Smith-Apeldoorn, et al.
Psychopharmacology (2021) Vol. 239, Iss. 1, pp. 15-33
Closed Access | Times Cited: 111
Nina Schimmers, Joost J. Breeksema, Sanne Y. Smith-Apeldoorn, et al.
Psychopharmacology (2021) Vol. 239, Iss. 1, pp. 15-33
Closed Access | Times Cited: 111
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
Jennifer Jones, Camilo F. Mateus, Robert Malcolm, et al.
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 102
Jennifer Jones, Camilo F. Mateus, Robert Malcolm, et al.
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 102
Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso, et al.
Brain Sciences (2021) Vol. 11, Iss. 7, pp. 856-856
Open Access | Times Cited: 86
Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso, et al.
Brain Sciences (2021) Vol. 11, Iss. 7, pp. 856-856
Open Access | Times Cited: 86
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Kyle T. Greenway, Nicolas Garel, Lisa Jerome, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 6, pp. 655-670
Closed Access | Times Cited: 72
Kyle T. Greenway, Nicolas Garel, Lisa Jerome, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 6, pp. 655-670
Closed Access | Times Cited: 72
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Sandra J Drozdz, Akash Goel, Matthew W McGarr, et al.
Journal of Pain Research (2022) Vol. Volume 15, pp. 1691-1706
Open Access | Times Cited: 55
Sandra J Drozdz, Akash Goel, Matthew W McGarr, et al.
Journal of Pain Research (2022) Vol. Volume 15, pp. 1691-1706
Open Access | Times Cited: 55
Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
David S. Mathai, Sandeep M. Nayak, David B. Yaden, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 827-836
Closed Access | Times Cited: 30
David S. Mathai, Sandeep M. Nayak, David B. Yaden, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 827-836
Closed Access | Times Cited: 30
Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence‐based prediction, expert evaluation, clinical corroboration and mechanism of action analyses
Zhenxiang Gao, Theresa Winhusen, Maria P. Gorenflo, et al.
Addiction (2023) Vol. 118, Iss. 7, pp. 1307-1319
Open Access | Times Cited: 24
Zhenxiang Gao, Theresa Winhusen, Maria P. Gorenflo, et al.
Addiction (2023) Vol. 118, Iss. 7, pp. 1307-1319
Open Access | Times Cited: 24
Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review
Jérémie Richard, Albert Garcia‐Romeu
Current Addiction Reports (2025) Vol. 12, Iss. 1
Closed Access | Times Cited: 1
Jérémie Richard, Albert Garcia‐Romeu
Current Addiction Reports (2025) Vol. 12, Iss. 1
Closed Access | Times Cited: 1
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial
Rebecca L Rothberg, Nour Azhari, Nancy A. Haug, et al.
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 150-158
Closed Access | Times Cited: 65
Rebecca L Rothberg, Nour Azhari, Nancy A. Haug, et al.
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 150-158
Closed Access | Times Cited: 65
“This Is Something That Changed My Life”: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders
Özden Merve Mollaahmetoğlu, Johanna Louise Keeler, Katherine J. Ashbullby, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 41
Özden Merve Mollaahmetoğlu, Johanna Louise Keeler, Katherine J. Ashbullby, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 41
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, et al.
Addiction Neuroscience (2022) Vol. 3, pp. 100025-100025
Open Access | Times Cited: 33
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, et al.
Addiction Neuroscience (2022) Vol. 3, pp. 100025-100025
Open Access | Times Cited: 33
Toward Synergies of Ketamine and Psychotherapy
David S. Mathai, Victoria Mora, Albert Garcia‐Romeu
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 31
David S. Mathai, Victoria Mora, Albert Garcia‐Romeu
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 31
Active mechanisms of ketamine-assisted psychotherapy: A systematic review
Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo, et al.
Journal of Affective Disorders (2022) Vol. 315, pp. 105-112
Closed Access | Times Cited: 29
Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo, et al.
Journal of Affective Disorders (2022) Vol. 315, pp. 105-112
Closed Access | Times Cited: 29
Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study
Grant Jones, Matthew K. Nock
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Grant Jones, Matthew K. Nock
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings
Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra, et al.
Frontiers in Human Neuroscience (2023) Vol. 17
Open Access | Times Cited: 19
Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra, et al.
Frontiers in Human Neuroscience (2023) Vol. 17
Open Access | Times Cited: 19
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Psychopharmacology (2023) Vol. 240, Iss. 7, pp. 1547-1560
Open Access | Times Cited: 18
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Psychopharmacology (2023) Vol. 240, Iss. 7, pp. 1547-1560
Open Access | Times Cited: 18
Therapeutic potential of ketamine for alcohol use disorder
Stephen Worrell, Thomas J. Gould
Neuroscience & Biobehavioral Reviews (2021) Vol. 126, pp. 573-589
Closed Access | Times Cited: 34
Stephen Worrell, Thomas J. Gould
Neuroscience & Biobehavioral Reviews (2021) Vol. 126, pp. 573-589
Closed Access | Times Cited: 34
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing
Jennifer Swainson, Larry J. Klassen, Stefan Brennan, et al.
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 239-251
Open Access | Times Cited: 25
Jennifer Swainson, Larry J. Klassen, Stefan Brennan, et al.
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 239-251
Open Access | Times Cited: 25
